Eledon Pharmaceuticals, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Verona Pharma plc entered into agreements that give the company access to as much as $650m in new debt and other financing, bringing its new cash potential to more than $1bn after starting the year w

Post-transplantation immunosuppression has come a long way: the first immunosuppressive, azathioprine, was developed in the 1960s and had one-year survival rates of 50-60%. Calcineurin inhibitors came

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning